Sole Development Sample Clauses

Sole Development. If either Sanofi or BMS wishes to pursue the development of any New Indication or Line Extension, such Party (the “Proposing Party”‘) shall propose such development to the other Party (the “Other Party”) in the context of the Development Committee. If the Other Party decides not to pursue such development, as evidenced by its negative vote in the Development Committee with respect to such development and irrespective of whether such Party has the Lead for the Product with respect to which such development is proposed, then the Development Committee shall submit such proposal to the License Steering Committee, which shall decide whether the Proposing Party may proceed alone with such development. If the License Steering Committee agrees to permit such sole development, the Proposing Party shall be entitled to undertake such development at its sole cost and expense.
Sample 1Sample 2See All (4)
AutoNDA by SimpleDocs
Sole Development. If the Parties decide a Maritime Link Expansion is necessary and one Party decides not to invest in a Maritime Link Expansion, the other Party has the right to proceed to complete such a Maritime Link Expansion on its own.
Sample 1
Sole Development. Until the definitive supply agreement described in Section 8.3 has been executed by the Parties, Cephalon agrees to supply Sanofi-Synthelabo and Sanofi-Synthelabo agrees to purchase exclusively from Cephalon, Sanofi-Synthelabo's requirements of Cephalon Compounds and Development Compounds for any studies for which Sanofi-Synthelabo has undertaken Sole Development pursuant to Article 11. Cephalon may engage third party manufacturers to produce the Cephalon Compounds and Development Compound with the prior written consent of Sanofi-Synthelabo, which consent shall not be unreasonably withheld. Cephalon shall provide all clinical and pre-clinical supply At Cost. All such supplies shall be in dosage form and packaging as specified by Sanofi-Synthelabo.
Sample 1
Sole Development. If either Party presents a proposal to the JRC to include in the Discovery Program the development of an Immunoconjugate and it is not included in the Discovery Program pursuant to Section 2.11(a), then either Party may, at its option and at its sole expense, conduct such development outside the scope of the Discovery Program (the “Solely Developed Immunoconjugate”). The sole-developing Party shall propose to the JRC the Solely Developed Immunoconjugate for inclusion in the Discovery Program when the Solely Developed Immunoconjugate has completed IND Preparation (unless the naked Antibody directed against the same Target as the Solely Developed Immunoconjugate is an IFM), and shall do so by submitting to the JRC a copy of the IND filing following the IND filing date. The JRC shall decide whether or not to include the Solely Developed Immunoconjugate into the Discovery Program (outside of the customary Opt-In Rights exercise under Section 5.4 below) with the non-developing Party’s representatives on the JRC having the final decision making authority solely with respect to such decision and the following shall apply:
Sample 1

Related to Sole Development

  • Joint Development If joint development is involved, the Recipient agrees to follow the latest edition of FTA Circular 7050.1, “Federal Transit Administration Guidance on Joint Development.”

  • Clinical Development Licensee will have sole responsibility for and sole decision making over the clinical development of any Product arising from the Research Program in the Field. Notwithstanding the foregoing, if Licensee wishes to conduct clinical development of a Development Candidate at Penn and Penn has the clinical expertise, interest and ability to run such a trial as assessed at Penn’s sole discretion, such a study will be conducted under a separate Clinical Trial Agreement to be negotiated by the Parties prior to initiation of such study. Such separate clinical trial agreement will include a detailed clinical development plan, including costs and time lines for conducting the Clinical Trial.

  • Adverse Developments Promptly after the Lessee acquires knowledge thereof, written notice of:

  • Independent Development Receiving Party may currently or in the future be developing information internally, or receiving information internally, or receiving information from other parties that may be similar to the Disclosing Party's Confidential Information. Accordingly, nothing in this Agreement will be construed as a representation or inference that Receiving Party will not develop or have developed products or services, that, without violation of this Agreement, might compete with the products or systems contemplated by the Disclosing Party's Confidential Information.

  • Research and Development (i) Advice and assistance in relation to research and development of Party B;

  • New Developments All ideas, inventions, discoveries, concepts, trade secrets, trademarks, service marks or other developments or improvements, whether patentable or not, conceived by Employee, alone or with others, at any time during the term of Employee’s employment, whether or not during working hours or on Employer’s premises, which are within the scope of or related to the business operations of Employer or its Affiliates (“New Developments”), shall be and remain the exclusive property of Employer. Employee agrees that any New Developments which, within one year after the cessation of employment with Employer, are made, disclosed, reduced to a tangible or written form or description or are reduced to practice by Employee and which are based upon, utilize or incorporate Information shall, as between Employee and Employer, be presumed to have been made during Employee’s employment by Employer. Employee further agrees that Employee will not, during the term of Employee’s employment with Employer, improperly use or disclose any proprietary information or trade secrets of any former employer or other person or entity and that Employee will not bring onto Employer premises any unpublished document or proprietary information belonging to any such employer, person or entity unless consented to in writing by such employer, person or entity. At all times during the term of this Agreement and thereafter, Employee shall do all things reasonably necessary to ensure ownership of such New Developments by Employer, including the execution of documents assigning and transferring to Employer all of Employee’s rights, title and interest in and to such New Developments and the execution of all documents required to enable Employer to file and obtain patents, trademarks, service marks and copyrights in the United States and foreign countries on any of such New Developments.

  • Business Development Provide advice and assistance in business growth and development of Party B. 业务发展。对乙方的业务发展提供建议和协助。

  • Product Development Attach all requested documentation and attach additional pages as necessary. For all requirements include efforts of all Sublicensees. If not applicable, please so indicate by N/A.

  • Future Developments The Seller continuously monitors technological developments and applies them to Technical Data, document and information systems’ functionalities, production and methods of transmission. The Seller will implement and the Buyer will accept such new developments, it being understood that the Buyer will be informed in due time by the Seller of such new developments and their application and of the date by which the same will be implemented by the Seller.

  • Business Development Company Buyer is a business development company as defined in Section 202(a)(22) of the Investment Advisors Act of 1940.

Time is Money Join Law Insider Premium to draft better contracts faster.